viewMotif Bio PLC

Motif Bio has 'considerable potential upside', according to Shard


Newly-floated Motif Bio (LON:MFTB) has ‘considerable potential upside’, according to the number crunchers Shard Capital.

The company is developing a best-in-class antibiotic called iclaprim that it is hoped will be able to target resistant strains of bacteria.

Not just that, in iclaprim it has a drug candidate that is ready to go into the final phase of clinical trials and could be out in the market in 18 months.

Shard estimates Motif will probably need to spend around £20mln to carry out these studies, which might mean tapping investors. But more likely it will find an industry partner to foot the bill.

Motif’s current market capitalisation is just £21.2mln, which Shard points out points values the business at a fraction of its closest benchmark company, the US firm Paratek, which is worth £310mln.

“This strongly suggests that there is considerable upside potential in Motif,” said analyst Mark Brewer.

LON:MTFB/MotifBio/">Click here to read the reoport in full. It can be found under the Presentations and Company Media tab.

Quick facts: Motif Bio PLC

Price: 0.384 GBX

Market: AIM
Market Cap: £2.52 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



KORE Mining is cashed up and ready for exploration on 4 unique projects

KORE Mining (CVE: KORE) CEO Scott Trebilcock joined Steve Darling from Proactive to discuss the company, that is exploring 4 properties including their Imperial project which they just completed a positive PEA. Trebilcock tells Proactive about that gold project and also about their...

1 day, 15 hours ago

2 min read